Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

@article{Kirchheiner2004PharmacogeneticsOA,
  title={Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response},
  author={Julia Kirchheiner and Katharina Nickchen and Mark S Bauer and M L Wong and Julio Licinio and Ivar Roots and J{\"u}rgen Brockm{\"o}ller},
  journal={Molecular Psychiatry},
  year={2004},
  volume={9},
  pages={442-473}
}
Genetic factors contribute to the phenotype of drug response. We systematically analyzed all available pharmacogenetic data from Medline databases (1970–2003) on the impact that genetic polymorphisms have on positive and adverse reactions to antidepressants and antipsychotics. Additionally, dose adjustments that would compensate for genetically caused differences in blood concentrations were calculated. To study pharmacokinetic effects, data for 36 antidepressants were screened. We found that… Expand
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
TLDR
Key findings are the association between drug metabolic polymorphisms, mainly in cytochrome P450 genes, with variations in drug metabolic rates and side effects, and the influence of a 5-HT2C polymorphism in antipsychotic-induced weight gain. Expand
Pharmacogenetic Studies Investigating the Adverse Effects of Antipsychotics
TLDR
This review summarizes the findings of the previous research in the field of pharmacogenetic studies concerning antipsychotics and suggests an association between dopamine 2 receptor polymorphisms and a dopamine 3 receptor polymorphism and antipsychotic-induced tardive dyskinesia is suggested. Expand
Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy.
TLDR
This review summarizes the present knowledge of associations between cytochrome P450 isoenzymes and the efficacy and side effects of antipsychotics. Expand
Pharmacogenetics: antidepressant drug response
TLDR
Pharmacogenetic findings include an association between the l allele of the serotonin transporter gene (5-HTTLPR) and a better response to selective serotonin reuptake inhibitors and the ability to predict metabolizer status with a high degree of accuracy by genotyping for CYP2D6 and CYP 2C19 polymorphisms. Expand
Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study
TLDR
There are no strong associations between common functional genetic variants in drug metabolizing enzymes and dosing, safety, or efficacy of leading antipsychotics, strongly suggesting merely modest effects on the use of these medicines in most patients in typical clinical settings. Expand
The Impact of Drug and Gene Interaction on the Antipsychotic Medication for Schizophrenia
TLDR
A promising direction for future research in schizophrenia treatment lies behind the identification of the specific genetic contributors that affect drug response, especially those associated with cytochrome P450. Expand
The usefulness of genotyping cytochrome P450 enzymes in the treatment of depression
  • S. Dubovsky
  • Biology, Medicine
  • Expert opinion on drug metabolism & toxicology
  • 2015
TLDR
This review covers principles of pharmacogenetics and pharmacogenomics, previous analyses of pharmacokinetic and pharmacodynamics studies, newer studies of the predictive value of genetic testing in the treatment of depression, obstacles to implementation of geneticTesting in predicting treatment response and side effects, and suggestions for future research. Expand
Pharmacogenetic study of atypical antipsychotic drug response: Involvement of the norepinephrine transporter gene
  • A. Méary, G. Brousse, +8 authors P. Llorca
  • Medicine
  • American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
  • 2008
TLDR
The results suggest that two norepinephrine transporter gene polymorphisms are specifically involved in the variation of positive symptoms in schizophrenic patients. Expand
Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors
TLDR
The implementation of a stratified approach to medication with SSRIs in different metabolic phenotypes on a rational basis will require new studies assessing the association between clinical outcomes (such as adverse reactions) and genetically determined elevated plasma concentrations. Expand
Pharmacogenetic studies of drug response in schizophrenia
TLDR
Characterization of key pharmacogenetic genes before the start or change of antipsychotic treatment may help to improve the efficacy and safety of pharmacological treatments and there is growing evidence of the clinical and economic benefits of introducing pharmacogenetics information as a prescription aid in clinical settings. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 313 REFERENCES
Pharmacogenetics of antidepressant medication intolerance.
TLDR
Pharmacodynamic differences among patients due to variant 5-HT(2A) receptors appear to be more important than pharmacokinetic variation in determining paroxetine intolerance and pharmacogenetic markers may be useful in predicting antidepressant treatment outcome. Expand
Efficacy and Side-Effects of Clozapine: Testing for Association with Allelic Variation in the Dopamine D4 Receptor Gene
TLDR
Frequency of four known polymorphic sites affecting protein structure in the dopamine D4 receptor gene in 149 patients with schizophrenia or schizoaffective disorder treated with clozapine showed no significant differences in genotype counts between responders and non-responders, and no side-effect was found to be associated with genetic variants of the dopamineD4 receptor. Expand
Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype.
TLDR
CYP2D6 genotype is not a determinant of susceptibility to acute dystonic reactions but may be a contributory factor in antipsychotic drug-induced movement disorders including tardive dyskinesia. Expand
Pharmacogenetics of Tardive Dyskinesia: Combined Analysis of 780 Patients Supports Association with Dopamine D3 Receptor Gene Ser9Gly Polymorphism
TLDR
A small but significant contribution of the DRD3 ser9gly polymorphism to TD susceptibility that is demonstrable over and above population effects and the effect of age and gender on the phenotype is supported. Expand
Association between clozapine response and allelic variation in the 5-HT2C receptor gene
TLDR
The results indicate that the 5-HT2C receptor may contain the major site of action through which clozapine mediates its antipsychotic effects. Expand
Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study.
TLDR
Among the case- and control-patients using a CYP2D6-dependent antipsychotic drug, the poor metabolizers were more than four times more likely to start with antiparkinsonian medication than the extensive metabolizers, which can increase the risk of antipsychotics-induced extrapyramidal syndromes. Expand
D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine
TLDR
Brain metabolic and clinical response to clozapine are related to the D1 receptor genotype, and the DRD1 2,2 genotype significantly improved with clozAPine treatment, demonstrating a 30% decrease in the Brief Psychiatric Rating Scale positive symptoms. Expand
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.
TLDR
The present-day knowledge on the influence of the genetic variability in CYP2D6 on the clinical pharmacokinetics and therapeutic effects/adverse effects of psychotropic drugs is reviewed. Expand
Relationship between adverse effects of antipsychotic treatment and dopamine D2 receptor polymorphisms in patients with schizophrenia
TLDR
In conclusion, genetic variations in the DRD2 gene were no major predictors of the individually variable adverse effects from antipsychotic treatment in Caucasian schizophrenic patients. Expand
Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes
TLDR
YP2D6-impaired metabolic capacity may be a contributory factor in extrapyramidal drug side effects, and this enzyme is also involved in the metabolism of endogenous compounds, including neurotransmitters such as dopamine. Expand
...
1
2
3
4
5
...